Torrent Pharmaceuticals has been instructed to review its global manufacturing operations by the US Food and Drug Administration, as part of a warning letter sent to the Indian company by the agency over its local manufacturing facility in Indrad, Gujarat. The FDA inspected the plant in April this year.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?